Novel Allogenic CAR T Therapy Shows Responses in R/R Multiple Myeloma
High response rates were reported among patients with relapsed/refractory multiple myeloma who received treatment with P-BCMA-ALLO1, an investigational allogeneic BCMA-directed T-cell therapy, according to data from a phase 1/1b trial (NCT04960579) …